Parameter
| Biomarker | Sema5A | Full name | Semaphorin 5A | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Pathogenesis-related, therapeutic targets |
| Disease | Autoimmune Disease (AD) | Disease Subtypes | / | ||
| Organ | Spleen, thymus, lymphoid tissue | Test Sample / Technology Platform | Serum and peripheral blood mononuclear cells (ELISA, qRT-PCR, Western Blot) | ||
| Pathobiological Mechanisms | Elevated serum levels promote Th17 differentiation through the Sema5A-PlexinA1 axis and the PI3K-Akt-mTOR pathway. | ||||
| Clinical Availability Status | Research validation: Positively correlated with SLEDAI, lupus nephritis, and IL-17A levels. | ||||
| Notes and Dynamics | A novel therapeutic target for SLE, which also reflects immune dysregulation. | ||||